People · Operator
Named in public records as an officer, director or promoter · active 2014–2022 · Biotechnology, Pharmaceuticals, Other Health Care
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Edison Pharmaceuticals Inc | — | Biotechnology | Series C | $80.2M | $2.0B | 2014 |
| Capacity Bio, Inc. | — | Pharmaceuticals | Series B | $19.2M | $245.7M | 2022 |
| Imel Biotherapeutics, Inc. | — | Other Health Care | Series B | $15.0M | $222.3M | 2021 |
| NapaJen Pharma, Inc. | — | Pharmaceuticals | Pre-Seed | $500K | $12.1M | 2021 |
Taro Inaba at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Taro Inaba on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Isaac Cheng | 1 | 9 |
| Dylan Morris | 1 | 8 |
| Amy Wang | 1 | 5 |
| Carl Berg | 1 | 3 |
| Tomer Kariv | 1 | 3 |
| Carl E. Berg | 1 | 3 |
| Paul Avery | 1 | 2 |
| Guy Miller | 1 | 2 |
| Forrest Sawyer | 1 | 2 |
| Walter Olesiak | 1 | 2 |
| Kazuhiko Nonomura | 1 | 1 |
| Martin E. Thoolen | 1 | 1 |
| Forrest E. Sawyer | 1 | 1 |
| Martine Thoolen | 1 | 1 |
| Keith Tsukimura | 1 | 1 |
| Martin Thoolen | 1 | 1 |
| Kenneth Horne | 1 | 1 |
| Cristina Ghenoiu | 1 | 1 |
| Dori Pelled | 1 | 1 |
| Silvia Noiman, Ph.D. | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.